CD8+CD103+ Tumor–Infiltrating Lymphocytes Are Tumor-Specific Tissue-Resident Memory T Cells and a Prognostic Factor for Survival in Lung Cancer Patients
The DOI matches its Crossref record; 50 of the 51 references it cites were found in a registry or an index.
Abstract
We had previously demonstrated the role of CD103 integrin on lung tumor-infiltrating lymphocyte (TIL) clones in promoting specific TCR-mediated epithelial tumor cell cytotoxicity. However, the contribution of CD103 on intratumoral T cell distribution and functions and the prognosis significance of TIL subpopulations in non–small cell lung carcinoma (NSCLC) have thus far not been systematically addressed. In this study, we show that an enhanced CD103+ TIL subset correlates with improved early stage NSCLC patient survival and increased intraepithelial lymphocyte infiltration. Moreover, our results indicate that CD8+CD103+ TIL, freshly isolated from NSCLC specimens, display transcriptomic and phenotypic signatures characteristic of tissue-resident memory T cells and frequently express PD-1 and Tim-3 checkpoint receptors. This TIL subset also displays increased activation-induced cell death and mediates specific cytolytic activity toward autologous tumor cells upon blockade of the PD-1–PD-L1 interaction. These findings emphasize the role of CD8+CD103+ tissue-resident memory T cells in promoting intratumoral CTL responses and support the rationale for using anti–PD-1 blocking Ab to reverse tumor-induced T cell exhaustion in NSCLC patients.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Further research revealed that the presence of CD103+CD8+ TILs is a positive prognostic marker in several cancers [269-272].”
From Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition) (2021) · cites this paper as [270]
In the citing paper
“Previous studies demonstrated that enhanced CD8+CD103+ TRM TILs correlate with improved survival in patients with early stage NSCLC18 and with other types of cancer19.”
From Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial (2021) · cites this paper as [18]
Citations
Cites
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“types of advanced solid tumors, including NSCLC (43, 44).”
BackgroundTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Munger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072 · cited 1×
“both molecules has been reported to transmit a death signal to T cells (40, 41).”
BackgroundUpregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565
The developmental pathway for CD103+CD8+ tissue-resident memory T cells of skin
Mackay, L. K., Rahimpour, A., Ma, J. Z., Collins, N., Stock, A. T., Hafon, M.-L., Vega-Ramos, J., Lauzurica, P., Mueller, S. N., Stefanovic, T., et al. (2013) · Nature Immunology · doi:10.1038/ni.2744 · Cited by 1,331 · cited 5×
“Indeed, downregulation of SIP1 was observed in CD103CD8 TRM T cells (18) and appeared to be required for their retention in peripheral tissues (28).”
BackgroundInfluentialFourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307 · cited 1×
“Among these inhibitory receptors, CTLA-4, PD-1, and Tim3 appeared to be associated with T cell exhaustion in chronic viral infections (35–38) and tumor progression (39).”
BackgroundPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors
Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,111 · cited 1×
“In the latter and present studies, CD103 T cells expressed high levels of PD-1, which has been defined as a biomarker of tumor-specific T cells (33).”
BackgroundSkin infection generates non-migratory memory CD8+ TRM cells providing global skin immunity
Jiang, X., Clark, R. A., Liu, L., Wagers, A. J., Fuhlbrigge, R. C., & Kupper, T. S. (2012) · Nature · doi:10.1038/nature10851 · Cited by 891 · cited 1×
“TRM T cells are highly activated T lymphocytes that reside within a variety of peripheral tissues, including intestine (17, 20), brain (21), skin (22, 23), and lung”
Background
Cited by
Items 201–300 of 661
Altorki, N. K., Walsh, Z. H., Melms, J. C., Port, J. L., Lee, B. E., Nasar, A., Spinelli, C., Caprio, L., Rogava, M., Ho, P., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-44195-x · Cited by 52
“An increase in the proportion of intra-tumoral CD103 + and T RM -like tumor-in fi ltrating lymphocytes is associated with improved responses to immune checkpoint inhibition as well as improved survival in a variety of tumors, including melanoma,lungcancer,headand neck,and bladdercancer 25,29,30,34 .”
Assessing personalized responses to anti-PD-1 treatment using patient-derived lung tumor-on-chip
Veith, I., Nurmik, M., Mencattini, A., Damei, I., Lansche, C., Brosseau, S., Gropplero, G., Corgnac, S., Filippi, J., Poté, N., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101549 · Cited by 63
“Of note, in agreement with the literature, 34 our previous analysis 35,36 showed that NSCLC CTLs are essentially effector memory (CD45RO + ) or terminally differentiated effector memory cells (CD45RA + ), negative for CD62L, CD28, CCR7, and TCF1, with an exhausted T cell profile (PD1 + , TIM3 + ,…”
ResultSelf-citationEiva, M. A., Omran, D. K., Chacon, J. A., & Powell, D. J. (2021) · European Journal of Immunology · doi:10.1002/eji.202149329 · Cited by 51
Tissue-resident immunity in the lung: a first-line defense at the environmental interface
Zazara, D. E., Belios, I., Lücke, J., Zhang, T., & Giannou, A. D. (2022) · Seminars in Immunopathology · doi:10.1007/s00281-022-00964-2 · Cited by 48
“Interestingly, enhanced proliferation of CD103+ T cells in tumors with high CD8+ T cell numbers was associated with a prolonged survival, a finding likely identifying CD8+CD103+ TRM cell infiltration as a positive prognostic factor [70, 286].”
BackgroundColorectal cancer: A paradigmatic model for cancer immunology and immunotherapy
Ijsselsteijn, M. E., Pamplona, R. S., Hermitte, F., & de Miranda, N. F. C. C. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2019.05.003 · Cited by 54
Kim, A., Lee, S. J., Ahn, J., Park, W. Y., Shin, D., Lee, C. H., Kwon, H., Jeong, Y. J., Ahn, H. Y., Hoseok, I., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0224430 · Cited by 48
Neoantigen-Specific Adoptive Cell Therapies for Cancer: Making T-Cell Products More Personal
Bianchi, V., Harari, A., & Coukos, G. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01215 · Cited by 49
Prognostic significance of resident CD103+CD8+T cells in human colorectal cancer tissues
Hu, W., Sun, R., Chen, L., Zheng, X. W., & Jiang, J. (2019) · Acta Histochemica · doi:10.1016/j.acthis.2019.05.009 · Cited by 47
van der Woude, L. L., Gorris, M. A. J., Wortel, I. M. N., Creemers, J. H. A., Verrijp, K. N., Monkhorst, K., Grünberg, K., van den Heuvel, M. M., Textor, J. C., Figdor, C. G., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005248 · Cited by 49
Varn, F. S., Andrews, E. H., Mullins, D. W., & Cheng, C. (2016) · Nature Communications · doi:10.1038/ncomms10248 · Cited by 50
Griffith, B. D., & Frankel, T. L. (2024) · Cancers · doi:10.3390/cancers16030472 · Cited by 50
“Similarly, in a preclinical head and neck cancer model, induction of local T RM -like cells inhibited tumor growth [83] in lung cancer, wherein T RM -like cells improved survival [81].”
BackgroundAnichini, A., Tassi, E., Grazia, G., & Mortarini, R. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2147-7 · Cited by 47
Smazynski, J., & Webb, J. R. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01741 · Cited by 47
Löffek, S. (2018) · Journal of Oncology · doi:10.1155/2018/9732939 · Cited by 49
T-cell-based breast cancer immunotherapy
Pilipow, K., Darwich, A., & Losurdo, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.05.019 · Cited by 45
Hewavisenti, R., Ferguson, A. L., Wang, K. Y. X., Jones, D., Gebhardt, T., Edwards, J. J., Zhang, M., Britton, W. J., Yang, J. Y. H., Hong, A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000452 · Cited by 45
“17 18 Mechanistically, a recent study has shown that these cells play an important role in preventing tumor metastasis by maintaining a stage of immune equilibrium.”
Pradhan, M., Chocry, M., Gibbons, D. L., Sepesi, B., & Cascone, T. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-573 · Cited by 48
Genetically driven CD39 expression shapes human tumor‐infiltrating CD8 + T‐cell functions
Gallerano, D., Ciminati, S., Grimaldi, A., Piconese, S., Cammarata, I., Focaccetti, C., Pacella, I., Accapezzato, D., Lancellotti, F., Sacco, L., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33131 · Cited by 45
Snyder, M. E., Sembrat, J., Noda, K., Myerburg, M. M., Craig, A., Mitash, N., Harano, T., Furukawa, M., Pilewski, J. M., McDyer, J. F., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202006-2403oc · Cited by 45
Jin, K., Yu, Y., Zeng, H., Liu, Z., You, R., Zhang, H., Liu, C., Su, X., Yan, S. R., Chang, Y., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01725-6 · Cited by 44
“Unlike that TRM cells mostly infiltrate in epithelial regions in ovarian cancer [13] and lung cancer [14], more TRM cells are infiltrated in normal urothelial regions than the intratumoural ones in MIBC tissues.”
BackgroundHu, F., Wang, W., Fang, C., & Bai, C. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112260 · Cited by 43
Prognostic significance of CD103+ immune cells in solid tumor: a systemic review and meta-analysis
Kim, Y.-H., Shin, Y., & Kang, G. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-40527-4 · Cited by 42
Leclerc, M., Mezquita, L., Nerville, G. G. D., Tihy, I., Malenica, I., Chouaïb, S., & Mami‐Chouaib, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01505 · Cited by 44
“As CD8 tumor-infiltrating T lymphocytes (TIL) express a large panel of immune checkpoints, including TIM-3, LAG-3, TIGIT, and BTLA (32, 33), several neutralizing antibodies toward these inhibitory receptors are under development for use as drugs in patients with cancer, including lung cancer.”
Self-citationSolomon, B., Young, R. J., Bressel, M., Cernelc, J., Savas, P. S., Liu, H. Y.-H., Urban, D., Thai, A. A., Cooper, C. L., Fua, T. F., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz271 · Cited by 40
The tumour immune landscape and its implications in cutaneous melanoma
Attrill, G. H., Ferguson, P. M., Palendira, U., Long, G. V., Wilmott, J. S., & Scolyer, R. A. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12926 · Cited by 45
“CD103+ tumour-resident memory CD8+ T cells have been shown to be positively correlated with survival in a wide range of solid tumours of different types and stages (Djenidi et al., 2015; Ling et al., 2007; Webb et al., 2014; Workel et al., 2016).”
BackgroundThe Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer
Beumer‐Chuwonpad, A., Taggenbrock, R. L. R. E., Ngo, T. A., & van Gisbergen, K. P. J. M. (2021) · Cells · doi:10.3390/cells10092234 · Cited by 41
“Differences may exist between TRM populations, given that TRM extracted from NSCLC and melanoma do not express CTLA-4 [20,89] and TRM originating from ovarian cancer only weakly express CTLA-4, TIM-3 and LAG-3 [127].”
BackgroundResultInfluentialCorgnac, S., Damei, I., Gros, G., Caidi, A., Terry, S., Chouaïb, S., Deloger, M., & Mami‐Chouaib, F. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004527 · Cited by 44
Self-citationvan Gisbergen, K. P. J. M., Zens, K. D., & Münz, C. (2021) · European Journal of Immunology · doi:10.1002/eji.202049062 · Cited by 39
Balança, C.-C., Scarlata, C., Michelas, M., Devaud, C., Sarradin, V., Franchet, C., Martínez-Gómez, C., Gomez‐Roca, C., Tosolini, M., Heaugwane, D., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0855 · Cited by 45
“In patients with cancer, CD8þ T cells expressing Trmmarkers have been identified (10, 11) and seem to overlap with exhausted T cells at tumor sites.”
BackgroundResident memory T cells in tumor-distant tissues fortify against metastasis formation
Christian, L. S., Wang, L., Lim, B. J. W., Deng, D., Wu, H., Wang, X., & Li, Q.-J. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109118 · Cited by 40
“For patients with breast, lung, or ovarian cancer, the abundance of CD8 + CD103 + T RM s strongly correlated with longer disease-free survival (Djenidi et al., 2015; Wang et al., 2016; Webb et al., 2014).”
Yan, Q., Li, S. C., He, L., & Chen, N. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1476365 · Cited by 42
Hope, J. L., Stairiker, C. J., Bae, E., Otero, D. C., & Bradley, L. M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01595 · Cited by 44
“Previous studies have shown that human lung tumor-infiltrating CD8 T cells express high levels of CD103 and CD69, and low levels of CD62L and CCR7, suggestive of TRM which retain characteristics of activated cells and induce rapid and effective responses against disease (174).”
BackgroundThe role and therapeutic implications of T cells in cancer of the lung
Neeve, S. A., Robinson, B. W. S., & Fear, V. S. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1076 · Cited by 39
Jung, J. H., Lee, J. S., Kim, Y., Lee, C., Yoo, B., Shin, E., & Hong, S. (2020) · Clinical & Translational Immunology · doi:10.1002/cti2.1140 · Cited by 38
Zhao, H., Yin, X., Wang, L., Liu, K., Liu, W., Bo, L., & Wang, L. (2023) · Scientific Data · doi:10.1038/s41597-023-02032-2 · Cited by 38
Genealogy, Dendritic Cell Priming, and Differentiation of Tissue-Resident Memory CD8+ T Cells
Enamorado, M., Khouili, S. C., Iborra, S., & Sancho, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01751 · Cited by 38
Skin‐resident memory T cells as a potential new therapeutic target in vitiligo and melanoma
Willemsen, M., Linkutė, R., Luiten, R. M., & Matos, T. R. (2019) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12803 · Cited by 39
“Tumor infiltration of CD8+ T cells exhibiting a resident phenotype (CD69+ CD103+ and/or CD103+) correlates with a more favorable prognosis for various human cancers (Djenidi et al., 2015; Koh et al., 2017; Wang et al., 2015; Webb, Milne, Watson, Deleeuw, & Nelson, 2014).”
BackgroundQin, S., Yu, Y., Guan, H., Yang, Y., Sun, F., Sun, Y., Zhu, J., Xing, L., Yu, J., & Sun, X. (2021) · Aging · doi:10.18632/aging.202981 · Cited by 37
Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC
Facchinetti, F., Marabelle, A., Rossi, G., Soria, J., Besse, B., & Tiseo, M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.05.027 · Cited by 43
Self-citationSei, S., Ahadova, A., Keskin, D. B., Bohaumilitzky, L., Gebert, J. F., Doeberitz, M. V. K., Lipkin, S. M., & Kloor, M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1147590 · Cited by 38
Nose, Y., Saito, T., Yamamoto, K., Yamashita, K., Tanaka, K., Yamamoto, K., Makino, T., Takahashi, T., Kawashima, A., Haruna, M., et al. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03240-2 · Cited by 37
Leem, G., Jeon, M., Kim, K. W., Jeong, S., Choi, S. J., Lee, Y. J., Kim, E.-S., Lee, J.-I., Ha, S. Y., Park, S., et al. (2021) · Thorax · doi:10.1136/thoraxjnl-2021-217001 · Cited by 37
Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines
McFall-Boegeman, H., & Huang, X. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2029415 · Cited by 36
Resident Memory T Cells as Surrogate Markers of the Efficacy of Cancer Vaccines
Nizard, M., Roussel, H., & Tartour, É. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2364 · Cited by 38
“In human cancer, various recent studies have shown that infiltration of tumors by CD103þCD8þ T cells was correlated with better clinical outcome in patients with lung cancer, ovarian cancer, and bladder cancer (11).”
ResultObeid, J. M., Wages, N. A., Hu, Y., Deacon, D. H., & Slingluff, C. L. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1908-4 · Cited by 38
“This sampling was based on similar strategies previously described [20, 22].”
MethodForoutan, M., Molania, R., Pfefferle, A., Behrenbruch, C., Scheer, S., Kallies, A., Speed, T. P., Cursons, J., & Huntington, N. D. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-21-0137 · Cited by 37
“However, several previous studies reported associations between CD8 Res cells and better response to ICBs and improved survival outcome [24-26].”
BackgroundResultInfluentialLosurdo, A., Scirgolea, C., Alvisi, G., Brummelman, J., Errico, V., Tommaso, L. D., Pilipow, K., Colombo, F., Fernandes, B., Peano, C., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02595-z · Cited by 37
Two sides of the same coin: Protective versus pathogenic CD4 + resident memory T cells
Oja, A. E., van Lier, R. A. W., & Hombrink, P. (2022) · Science Immunology · doi:10.1126/sciimmunol.abf9393 · Cited by 35
Immune checkpoint blockade: timing is everything
Sinicrope, F. A., & Turk, M. J. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009722 · Cited by 35
Zhu, W., Liu, X., Yang, L., He, Q., Huang, D., & Tan, X. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176124 · Cited by 36
Integrin αE(CD103)β7 in Epithelial Cancer
Hoffmann, J. C., & Schön, M. P. (2021) · Cancers · doi:10.3390/cancers13246211 · Cited by 35
“Among these, CCR5 and CCR6 are thought to confer T-cell homing to the inflammatory tumor microenvironment [15].”
BackgroundInfluentialTissue-Resident Memory CD4+ T Cells Play a Dominant Role in the Initiation of Antitumor Immunity
Zhang, H., Zhu, Z., Modrak, S., & Little, A. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100852 · Cited by 37
Zhang, Y., Zhai, Q., Feng, X., Chen, D., Lu, Y., Hu, J., Xie, H., Zhou, L., Wu, J., & Zheng, S. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02519-z · Cited by 34
“49 mm2 field) for each stained core of HCC tissue [21, 22].”
BackgroundZhao, Q., Kong, L.-Y., Jiang, S., Tian, X., Wang, J., Hashizume, R., Hu, J., Jia, Z., Fowlkes, N. W., Yan, J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36430-2 · Cited by 34
Crosstalk between Innate Lymphoid Cells and Other Immune Cells in the Tumor Microenvironment
Flores‐Borja, F., Irshad, S., Gordon, P., Wong, F., Sheriff, I., Tutt, A. N. J., & Ng, T. (2016) · Journal of Immunology Research · doi:10.1155/2016/7803091 · Cited by 34
Formation of Tissue-Resident CD8+ T-Cell Memory
Dijkgraaf, F. E., Kok, L., & Schumacher, T. N. (2021) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a038117 · Cited by 33
Dornieden, T., Sattler, A., Reguant, A. P., Ruhm, A. H., Thiel, L. G., Bergmann, Y., Thole, L. M. L., Köhler, R., Kühl, A. A., Hauser, A. E., et al. (2021) · Journal of the American Society of Nephrology · doi:10.1681/asn.2020101528 · Cited by 33
Cell-intrinsic view of the aryl hydrocarbon receptor in tumor immunity
Dean, J. W., & Zhou, L. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.01.008 · Cited by 33
Editorial: Tissue Resident Memory T Cells
Mami‐Chouaib, F., & Tartour, É. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01018 · Cited by 31
Self-citationQu, Q.-X., Zhu, X.-Y., Du, W.-W., Wang, H.-B., Shen, Y., Zhu, Y.-B., & Chen, C. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00577 · Cited by 30
Merkler, D., Vincenti, I., Masson, F., & Liblau, R. S. (2022) · Current Opinion in Immunology · doi:10.1016/j.coi.2022.102211 · Cited by 30
Chu, Y., Liao, J., Li, J., Wang, Y., Yu, X.-J., Wang, J., Xu, X., Xu, L., Zheng, L., Xu, J., et al. (2019) · Journal of Cancer · doi:10.7150/jca.30354 · Cited by 33
“Recent studies have found that increased CD103+ tissue-resident CD8+ T cells are associated with improved survival in melanoma [8], lung cancer [15], and cervical cancer [16], suggesting that CD103+ T cells are a potential predictive biomarker.”
BackgroundResultMori, T., Tanaka, H., Deguchi, S., Yamakoshi, Y., Miki, Y., Yoshii, M., Tamura, T., Toyokawa, T., Lee, S., Muguruma, K., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0262455 · Cited by 33
Zareie, P., Weiss, E. S., Kaplan, D. H., & Mackay, L. K. (2025) · Nature Immunology · doi:10.1038/s41590-025-02145-3 · Cited by 29
“…immune checkpoint receptors, including programmed cell death protein 1 (PD-1), lymphocyte activation gene 3 (LAG-3) and T cell immunoglobulin and mucin domain-containing 3 (TIM-3) 80,84,98,109 , and indeed, immune checkpoint blockade can augment T RM cell function in certain settings 110 .”
Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes
Sun, Y., Yinwang, E., Wang, S., Wang, Z., Wang, F., Xue, Y., Zhang, W., Zhao, S., Mou, H., Chen, S., et al. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02104-w · Cited by 34
Epstein-Barr virus infection induces tissue-resident memory T cells in mucosal lymphoid tissues
Kirchmeier, D., Deng, Y., Rieble, L., Böni, M., Läderach, F., Schuhmachers, P., Valencia-Camargo, A. D., Murer, A., Caduff, N., Chatterjee, B., et al. (2024) · JCI Insight · doi:10.1172/jci.insight.173489 · Cited by 30
Paolini, L., Tran, T., Corgnac, S., Villemin, J.-P., Wislez, M., Arrondeau, J., Johannes, L., Ulmer, J., Vieillard, L.-V., Pineau, J., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009440 · Cited by 32
Self-citationKol, A., Lubbers, J. M., Terwindt, A. L. J., Workel, H. H., Plat, A., Wisman, G. B. A., Bart, J., Nijman, H. W., & de Bruyn, M. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1936391 · Cited by 29
Zhao, H., Wang, H., Zhao, Y., Sun, Q., & Ren, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.877689 · Cited by 32
Durgeau, A., Virk, Y., Gros, G., Voilin, E., Corgnac, S., Djenidi, F., Salmon, J., Adam, J., de Montpréville, V., Validire, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-07603-1 · Cited by 30
Self-citationLeón-Rodríguez, S. G. D., Aguilar-Flores, C., Gajón, J. A., Juárez-Flores, Á., Mantilla, A., Gerson-Cwilich, R., Martínez‐Herrera, J. F., Osorno, D. A. V., Gutiérrez-Quiroz, C. T., Buenaventura‐Cisneros, S., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008739 · Cited by 29
Tian, Y., Sun, Y., Gao, F., Koenig, M. R., Sunderland, A., Fujiwara, Y., Torphy, R. J., Chen, L., Edil, B. H., Schulick, R. D., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1538440 · Cited by 27
“Recent studies identified that some TILs bear TRM phenotype and are associated with better prognosis in cancer patients.(18,19) In this study, we analyzed TILs from human cancers relevant to TRM phenotype and CD28H expression.”
BackgroundHuman cancer germline antigen-specific cytotoxic T cell—what can we learn from patient
Hamid, M. A., Peng, Y., & Dong, T. (2020) · Cellular and Molecular Immunology · doi:10.1038/s41423-020-0468-x · Cited by 29
Proof of principle study of sequential combination atezolizumab and Vigil in relapsed ovarian cancer
Rocconi, R. P., Stevens, E., Bottsford-Miller, J. N., Ghamande, S. A., Elder, J. W., DeMars, L., Munkarah, A. R., Aaron, P. A., Stanbery, L., Wallraven, G., et al. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-021-00317-5 · Cited by 27
Draghi, A., Chamberlain, C. A., Khan, S., Papp, K., Lauss, M., Soraggi, S., Radic, H. D., Presti, M., Harbst, K., Gokuldass, A., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.705422 · Cited by 27
Tissue-resident memory T cells in the urogenital tract
Vidal, L. P., van Aalderen, M. C., Stark, R., & van Gisbergen, K. P. J. M. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00525-0 · Cited by 27
Tumor immunotherapy: Mechanisms and clinical applications
Nong, C., Guan, P., Li, L., Zhang, H., & Hu, H. (2022) · MedComm – Oncology · doi:10.1002/mog2.8 · Cited by 30
Yang, G., Cai, S., Hu, M., Li, C., Yang, L., Zhang, W., Sun, J., Sun, F., Xing, L., & Sun, X. (2024) · Journal of Translational Medicine · doi:10.1186/s12967-023-04839-4 · Cited by 30
“Emerging evidence has linked the quantity of T RM cells, mostly CD103 + CD8 + T RM (referred to by “T RM ” in this study unless otherwise noted), to better response to immunotherapy and better prognosis of patients with lung cancer [7–9].”
BackgroundHuang, H., Su, Y., Li, P.-H., Chiang, P., Huang, C.-H., Chen, C.-H., & Hsieh, M. (2018) · Scientific Reports · doi:10.1038/s41598-018-25944-1 · Cited by 27
Resident Memory T Cells and Their Effect on Cancer
Craig, D. J., Creeden, J. F., Einloth, K. R., Gillman, C. E., Stanbery, L., Hamouda, D., Edelman, G. M., Dworkin, L. D., & Nemunaitis, J. J. (2020) · Vaccines · doi:10.3390/vaccines8040562 · Cited by 30
“In addition, TRM cells isolated from lung carcinomas co-cultured with autologous tumor cells demonstrate enhanced cytotoxic activity in the presence of PD-1 targeting antibodies compared to those not treated with PD-1 antibodies [9].”
BackgroundLéon-Letelier, R. A., Castro-Medina, D. I., Badillo, O., Tepale-Segura, A., Huanosta-Murillo, E., Aguilar-Flores, C., León-Rodríguez, S. G. D., Mantilla, A., Fuentes‐Pananá, E. M., López-Macías, C. I. R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.583382 · Cited by 26
“Thus, this potentially terminally exhausted phenotype was also evaluated in mice immunized with MAA + Porins and with Porins-alone, observing in CD8 and in CD8 Trm TILs the co-expression of TIM-3 and PD-1 exclusively for the MAA + Porins immunization condition (Supplementary Figures 7A, B), these phenotypes have alrea…”
ResultImmunoregulatory and lipid presentation pathways are upregulated in human face transplant rejection
Win, T. S., Crisler, W. J., Dyring‐Andersen, B., Lopdrup, R. G., Teague, J. E., Zhan, Q., Barrera, V., Sui, S. H., Tasigiorgos, S., Murakami, N., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci135166 · Cited by 29
“Checkpoint molecules are also expressed by tissue-resident memory T cells, not as an indication of exhaustion, but likely as a mechanism to remain poised and functional long-term within peripheral tissues (28, 29).”
BackgroundPrognostic and therapeutic value of CD103+ cells in renal cell carcinoma
Zhou, J., Liu, L., Yang, T., & Lu, B. (2018) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2018.6025 · Cited by 27
“Previous studies have demonstrated that CD103 serves an important role in the cell lysis caused by tumor‑specific infiltrating lymphocytes via interacting with its ligand, E-cadherin, on the tumor cells, triggering lytic granule polarization and exocytosis (10,11).”
InfluentialYu, X., Zhang, L., Chaudhry, A., Rapaport, A. S., & Ouyang, W. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.6mr0320-234r · Cited by 27
Malignant Pleural Effusions—A Window Into Local Anti-Tumor T Cell Immunity?
Principe, N., Kidman, J., Lake, R., Lesterhuis, W. J., Nowak, A. K., McDonnell, A. M., & Chee, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672747 · Cited by 30
“Increased pretreatment frequencies of TRMs in tumors associate with improved survival (72, 74), and increase pre- or post-treatment frequencies associate with response to anti-PD-1 therapy in lung cancer patients (73).”
BackgroundTissue-resident memory T cells in the era of (Neo) adjuvant melanoma management
Plunkett, K. R., Armitage, J. D., Inderjeeth, A., McDonnell, A. M., Waithman, J. C., & Lau, P. K. H. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1048758 · Cited by 25
“Moreover, tumorinfiltrating TRM correlate with longer disease-free periods and OS in patients of cSCC (20, 21), breast (22), ovarian (23), endometrial (24), pancreatic ductal adenocarcinoma (25) and lung cancer (26, 27) which further exemplifies the importance of this T cell subset in cancer outcomes.”
BackgroundIL-12 drives the expression of the inhibitory receptor NKG2A on human tumor-reactive CD8 T cells
Fesneau, O., Samson, K. A., Rosales, W. K., Jones, B., Moudgil, T. L., Fox, B. A., Rajamanickam, V., & Duhen, T. M. (2024) · Nature Communications · doi:10.1038/s41467-024-54420-w · Cited by 25
Scherwitzl, I., Hurtado, A. M., Pierce, C. M., Vogt, S., Pampeno, C., & Meruelo, D. (2018) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2018.04.004 · Cited by 26
Tissue-resident memory-like T cells in tumor immunity: Clinical implications
Dhodapkar, M. V., & Dhodapkar, K. M. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101415 · Cited by 25
Edwards, J. J., Ferguson, P. M., Lo, S., da Silva, I. P., Colebatch, A. J., Lee, H., Saw, R. P. M., Thompson, J. F., Menzies, A. M., Long, G. V., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0835 · Cited by 26
“2B), despite increasing evidence that CD103þCD8þ tumor-resident T cells (Trm) represent a subset of T cells specific for tumor antigens (21, 22).”
BackgroundShen, Y., Li, X.-L., Li, Y., Shan, Z., Zhao, Y., Cheng, P., Zhao, Z., Zhang, J., Chen, W., Zhuang, Y., et al. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03105-0 · Cited by 24
Kwiecień, I., Rutkowska, E., Sokołowski, R., Bednarek, J., Raniszewska, A., Jahnz‐Różyk, K., Rzepecki, P., & Domagala-Kulawik, J. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.864497 · Cited by 26
“CD8+ T cells with effector markers have been identified in cancer patients and appear to overlap with depleted T cells at tumor sites (20, 21).”
BackgroundMechanisms and biomarkers of immune-related adverse events in gastric cancer
Ding, P., Liu, P., Meng, L., & Zhao, Q. (2023) · European journal of medical research · doi:10.1186/s40001-023-01365-3 · Cited by 25
Kwiecień, I., Skirecki, T., Polubiec-Kownacka, M., Raniszewska, A., & Domagala-Kulawik, J. J. (2019) · Cancers · doi:10.3390/cancers11040567 · Cited by 24
“described the phenotype of TIL in lung cancer being in the majority activated, memory CD8+ cells [36].”
BackgroundRuiz, M. G., Isla, D., Cruellas, M., Gálvez, E. M., Lastra, R. P., Ocáriz, M., Paño, J. R., Ramírez-Labrada, A., Sesma, A., Torres-Ramón, I., et al. (2020) · Cells · doi:10.3390/cells9061525 · Cited by 27
“The data showed that high CM/Eff T cell ratio correlated with increased tumor PD-L1 expression and longer PFS (91 vs. 215 days).”
BackgroundResultInfluentialEngineering Vaccines for Tissue‐Resident Memory T Cells
Knight, F. C., & Wilson, J. T. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202000230 · Cited by 26
Wang, P., Huang, B. Y., Gao, Y., Yang, J., Liang, Z., Zhang, N., Fu, X., & Li, L. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.02.002 · Cited by 26
Zhong, C., Lang, Q., Yu, J., Wu, S., Xu, F., & Tian, Y. (2020) · Clinical & Experimental Immunology · doi:10.1111/cei.13413 · Cited by 24
Tsuji, T., Eng, K. H., Matsuzaki, J., Battaglia, S., Szender, J. B., Miliotto, A. J., Gnjatic, S., Bshara, W., Morrison, C. D., Lele, S., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27666 · Cited by 23
Ippolito, S., Dalmazi, G. D., Pani, F., Sabini, E., & Caturegli, P. (2021) · Thyroid · doi:10.1089/thy.2021.0165 · Cited by 23
“…also present as a sub-class of tumor infiltrating lymphocytes in cancer, and even in this setting, a higher expression of immune-checkpoints has been demonstrated (17); in this light, it has been hypothesized that this lymphoid population may be specifically involved in the outcomes of ICI therapies.”
Metadata
- Authors
- Djenidi, F., Adam, J., Goubar, A., Durgeau, A., Meurice, G., de Montpréville, V., Validire, P., Besse, B., & Mami-Chouaib, F.
- Affiliations
- Université Paris-Sud (FR)
- INSERM Unité 1186 , 94805 Villejuif ,
- Institute Mutualiste Montsouris (FR)
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-01
- Volume
- 194
- Issue
- 7
- Pages
- 3475-3486
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1895620535
- Cited by
- 622
- References
- 51
- Citations by year
- 2026: 34 · 2025: 61 · 2024: 51 · 2023: 55 · 2022: 63 · 2021: 81 · 2020: 72 · 2019: 70 · 2018: 66 · 2017: 27 · 2016: 28 · 2015: 13
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Institut Gustave-Roussy
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tumor-infiltrating lymphocytes, tissue-resident memory T cells, non-small cell lung cancer, PD-1, TIM-3, immune checkpoint blockade, T cell exhaustion, intraepithelial lymphocytes, patient survival, prognostic factors, T cell cytotoxicity
- MeSH terms
- Hepatitis A Virus Cellular Receptor 2, Aged, Aged, 80 and over, Carcinoma, Non-Small-Cell Lung, Cytotoxicity, Immunologic, Female, Humans, Immunologic Memory, Lung Neoplasms, Lymphocyte Activation, Male, Membrane Proteins, Middle Aged, Neoplasm Staging, Organ Specificity, Prognosis, Risk Factors, Antigens, CD, Immunophenotyping, Lymphocytes, Tumor-Infiltrating, CD8 Antigens, Gene Expression Profiling, Integrin alpha Chains, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.